Aren't you overthinking this? Why wouldn't AMRN just create new labels for a generic version right on the existing assembly line? Simple manufacturing. Same pill, different bottle. Price slightly lower. Additional costs are almost nothing. Use up more API and the auto-switching to GenCepa competes with the Hikma's of the world. If we're already price competitive, minimal price change is needed.
Market Data 
Markets 
AI
